Immune checkpoint therapies, such as PD-L1 or PD-1 blockade therapy, for MCC, have recently shown successful results.30 31 Approximately 50% of patients, however, remain without durable benefit from these epochal treatments.32 Further immune checkpoint treatment strategies are therefore still required. This evidence concerns the gene PDCD1 and Merkel cell skin cancer.